**Bacillus subtilis** as a Platform for Molecular Characterisation of Regulatory Mechanisms of *Enterococcus faecalis* Resistance against Cell Wall Antibiotics

Chong Fang¹, Emanuel Stiegeler¹*, Gregory M. Cook², Thorsten Mascher¹, Susanne Gebhard¹*

¹ Department Biology I, Microbiology, Ludwig-Maximilians-Universität München, Martinsried, Germany, ² Department of Microbiology and Immunology, Otago School of Medical Sciences, University of Otago, Dunedin, New Zealand

**Abstract**

To combat antibiotic resistance of *Enterococcus faecalis*, a better understanding of the molecular mechanisms, particularly of antibiotic detection, signal transduction and gene regulation is needed. Because molecular studies in this bacterium can be challenging, we aimed at exploiting the genetically highly tractable Gram-positive model organism *Bacillus subtilis* as a heterologous host. Two fundamentally different regulators of *E. faecalis* resistance against cell wall antibiotics, the bacitracin sensor BcrR and the vancomycin-sensing two-component system VanS-VanR, were produced in *B. subtilis* and their functions were monitored using target promoters fused to reporter genes (*lacZ* and *luxABCDE*). The bacitracin resistance system BcrR-BcrAB of *E. faecalis* was fully functional in *B. subtilis*, both regarding regulation of bcrAB expression and resistance mediated by the transporter BcrAB. Removal of intrinsic bacitracin resistance of *B. subtilis* increased the sensitivity of the system. The *lacZ* and *luxABCDE* reporters were found to both offer sensitive detection of promoter induction on solid media, which is useful for screening of large mutant libraries. The VanS-VanR system displayed a gradual dose-response behaviour to vancomycin, but only when produced at low levels in the cell. Taken together, our data show that *B. subtilis* is a well-suited host for the molecular characterization of regulatory systems controlling resistance against cell wall active compounds in *E. faecalis*. Importantly, *B. subtilis* facilitates the careful adjustment of expression levels and genetic background required for full functionality of the introduced regulators.

---

**Introduction**

*Enterococcus faecalis* is one of the most common causes of nosocomial infections. Increasing incidences of infections with antibiotic resistant strains, particularly with vancomycin resistant enterococci (VREs), therefore pose a major health risk [1,2]. Vancomycin is a glycopeptide antibiotic that targets the lipid II cycle of cell wall biosynthesis by binding to the terminal D-alanyl-D-alanine (D-Ala-D-Ala) moiety of peptidoglycan precursors on the surface of the cell, thus inhibiting their incorporation into the cell wall [3]. Many other antimicrobial substances also target the lipid II cycle [4], including bacteriocins and mammalian defensins [5,6], both of which will likely be encountered by *E. faecalis* in its natural gut habitat. Furthermore, many enterococcal isolates were found to be highly resistant against bacitracin [7,8], yet another inhibitor of cell wall biosynthesis [9].

The molecular mechanisms leading to resistance are often well known. In the case of vancomycin, high-level resistance is for example ensured by target alteration through replacement of the terminal D-Ala-D-Ala by D-Ala-D-lactate. In VanA-type strains, this is accomplished through the action of the VanHAX system, while in VanB-type strains the VanHBBXB proteins mediate resistance [10,11]. High-level bacitracin resistance of *E. faecalis* is conferred by the ATP-binding cassette (ABC) transporter BcrAB, which presumably removes the antibiotic from its site of action (i.e. the cytoplasmic membrane) [7]. The precise mechanism of bacitracin resistance by ABC-transporters is not yet fully understood [12].

The expression of most resistance genes is induced in the presence of the respective antibiotic. For example, the van operons are induced in the presence of vancomycin by the two-component systems VanS-VanR or VanSb-VanRb for VanA- and VanB-type resistance, respectively [11,13]. Bacitracin-dependent induction of bcrAB is mediated by the one-component transmembrane regulator BcrR [7,14]. While the regulators and target promoters, as well as the conditions leading to induction are known, we lack in-depth understanding of the molecular mechanisms of regulation. For example, while both VanS and VanSb respond to vancomycin,
their sensory domains differ considerably in size with 37 amino acids for VanS and 103 residues for VanSp, and share only low sequence similarity [13]. It is therefore difficult to envisage the same sensing mechanism for both proteins. It is similarly unclear how BcrR detects bacitracin, because the protein lacks any obvious extracellular domains but is nevertheless able to directly interact with its substrate [14,16]. Additionally, it is not known how a membrane-bound transcriptional regulator like BcrR activates transcription from its target promoter. While a direct interaction with RNA-polymerase has been proposed [16], experimental evidence is lacking to date.

Sensory perception of antimicrobial substances by bacteria is a first and essential step in antibiotic resistance, and a thorough understanding of the mechanisms involved would provide an important basis for the development of new drugs to combat resistance. However, in many genera, e.g. the enterococci, investigations are hampered by the difficulty to manipulate these bacteria genetically. Although more and more genetic tools are becoming available for enterococci, poor transformability of many strains, including clinical isolates, still impedes studies involving, for example, high-throughput or detailed mutagenic approaches. To circumvent these problems, heterologous hosts have been chosen, often using E. coli [17], or electro-transformable laboratory strains of E. faecalis [7,14]. The latter provide improved transformability, but no additional genetic tools, while the former host does not appear well suited to study resistance against cell wall active compounds, due to the major differences between the Gram-positive and Gram-negative cell envelope. Alternatively, Bacillus subtilis has been used successfully for the functional expression of the VanS-VanR two-component system of E. faecalis, as well as of the VanB-type resistance proteins [11,18]. Like E. coli, B. subtilis is easy to manipulate and a large number of genetic tools are available. The G+C contents of B. subtilis (43.5%) and of E. faecalis (37.5%) are comparable, which is of great advantage for heterologous gene expression. Furthermore, the transcription machinery in both organisms is sufficiently similar to facilitate the interaction of heterologous transcriptional regulators with the native machinery, as has been shown in vitro for activation of B. subtilis RNA polymerase by E. faecalis BcrR [16]. Importantly for the present application, the intrinsic resistance mechanisms of B. subtilis against cell wall antibiotics are well understood [19,20], allowing directed deletion of genes to create a clean genetic background.

In the present study, we have used two well-understood examples from E. faecalis to develop and validate B. subtilis as a platform for studying the regulatory mechanisms leading to resistance against cell wall-active antibiotics. To test the feasibility of our approach and determine the optimal genetic background of the host, we chose the one-component regulator BcrR and could show full functionality with highly similar behaviour to its native context. This set-up was then applied to the VanS-VanR two-component system. A previous attempt at heterologous expression of this system in B. subtilis had resulted in a constitutively active behaviour [18]. Optimization of expression levels and growth conditions now resulted in vancomycin-dependent induction of the target promoter, further supporting the suitability of B. subtilis as host organism.

Materials and Methods

Bacterial strains and growth conditions
All strains used in this study are listed in Table 1. E. coli DH5α and XL1-blue were used for cloning. E. coli and B. subtilis were grown routinely in Luria-Bertani (LB) medium at 37°C with agitation (200 rpm). B. subtilis was transformed by natural competence as previously described [21]. Selective media contained ampicillin (100 µg ml⁻¹ for E. coli), chloramphenicol (5 µg ml⁻¹ for B. subtilis), kanamycin (10 µg ml⁻¹ for B. subtilis), erythromycin 1 µg ml⁻¹ with lincomycin 25 µg ml⁻¹ (for macroline-lincosamide-streptogramin B (mls) resistance in B. subtilis) or spectinomycin (100 µg ml⁻¹ for B. subtilis). Bacitracin was supplied as the Zn²⁺-salt. Unless otherwise stated, media for strains carrying pXT-derived constructs contained 0.2% (w/v) xylose for target gene expression. Solid media contained 1.5% (w/v) agar. Growth was measured as optical density at 600 nm wavelength (OD₆₀₀).

Construction of plasmids and genetic techniques
All primer sequences used for this study are listed in Table 2; all plasmid constructs are listed in Table 1.

Transcriptional promoter fusions of P₄₆₀₀ to lacZ or bacterial luciferase (luxABCDE) were constructed in vectors pAc6 [22] or pH328 [23] by the sites of EcoRI/BamHI and EcoRI/SpeI, respectively, obtaining plasmids pSE601 and pNThux101, respectively. The transcriptional promoter fusion of P₄₆₀₀ to bacterial luciferase was cloned into the EcoRI and SpeI sites of vector pH328 creating plasmid pCF133. The exact regions contained in the constructs are given in Table 1.

For heterologous, xylose-inducible expression of bcrR or bcrR-bcrB in B. subtilis (pES701 and pES702) the respective DNA fragments were amplified from the plasmid pAMbcr1 [7] and cloned in the vector pXT [24] using the BamHI and EcoRI restriction sites, placing the genes under the control of the vector’s xyf₁ promoter. Plasmid pCF132 was constructed by inserting vanRSp₄₆₀₀ from E. faecalis V530 into the BamHI and HindIII sites of vector pXT for heterologous, xylose-inducible expression in B. subtilis.

Constructs for unmarked gene deletions in B. subtilis were cloned into the vector pMAD [25]. For each operon to be deleted, 800–1000 bp fragments located immediately before the start codon of the first gene (“up” fragment) and after the stop codon of the last gene (“down” fragment) were amplified. The primers were designed to create a 17–20 bp overlap between the PCR-products (Table 2), facilitating fusion of the fragments by PCR overlap extension and subsequent cloning into pMAD. Gene deletions were performed as previously described [25]. All constructs were checked for PCR-fidelity by sequencing, and all created strains were verified by PCR using appropriate primers.

Antimicrobial susceptibility assays
All cultures were grown in Mueller-Hinton (MH) medium for antibiotic susceptibility assays [26]. Minimal inhibitory concentration (MIC) of bacitracin and vancomycin were determined by broth-dilution assays. Freshly grown overnight cultures of B. subtilis in MH medium were used as inoculum at a dilution of 1:500. After 24 h incubation in the presence of two-fold serial dilutions of the antibiotic the MIC was scored as the lowest concentration where no growth was observed.

β-Galactosidase assays
Cells were inoculated from fresh overnight cultures and grown in LB medium at 37°C with aeration until they reached an OD₆₀₀ between 0.4 and 0.5. The cultures were split into 2 mL aliquots and challenged with different concentrations of bacitracin with one aliquot left untreated. After incubation for an additional 30 min at 37°C with aeration, the cultures were harvested and the cell pellets were frozen at −20°C. β-galactosidase activities were determined as described, with normalization to cell density [27].
Table 1. Plasmids and strains used in this study.

| Name                          | Description                        | Source       |
|-------------------------------|------------------------------------|--------------|
| **Vectors**                   |                                    |              |
| pAC6                          | Vector for transcriptional promoter fusions to lacZ in *B. subtilis*, integrates in amyE; cm’ | [22]         |
| pAH328                        | Vector for transcriptional promoter fusions to luxABCDDE in *B. subtilis*; integrates in sacA; cm’ | [23]         |
| pMAD                          | Vector for construction of unmarked deletions in *B. subtilis*, temperature sensitive replicon; mls’ | [25]         |
| pXT                           | Vector for xylose-inducible gene expression in *B. subtilis*; integrates in thrC; spc’ | [24]         |
| **Plasmids**                  |                                    |              |
| pAMbcR1                       | *E. coli-E. faecalis* shuttle vector containing a 4.7 kb EcoRI-fragment encompassing the bcrR-bcrABD locus of *E. faecalis* AR01/DGV5 | [7]          |
| pCF102                        | pMAD containing the joined “up” and “down” fragments for unmarked deletion of bcrRS-bceAB | This study   |
| pCF104                        | pMAD containing the joined “up” and “down” fragments for unmarked deletion of psdRS-psdAB | This study   |
| pCF119                        | pMAD containing the joined “up” and “down” fragments for unmarked deletion of yxdJK-yxdLM-yxeA | This study   |
| pCF132                        | pXT containing the vanR operon of *E. faecalis* V583 | This study   |
| pCF133                        | pAH328 containing P_\text{van}_{\text{up}} of *E. faecalis* V583 from -215 to +65 relative to the vanY start codon | This study   |
| pES601                        | pAC6 containing P_bcr of *E. faecalis* AR01/DGV5 from -219 to +170 relative to the bcrA start codon | This study   |
| pES701                        | pXT containing bcrR of *E. faecalis* AR01/DGV5 | This study   |
| pES702                        | pXT containing the bcrR-bcrAB region of *E. faecalis* AR01/DGV5 | This study   |
| pNTLux101                     | pAH328 containing P_bcr of *E. faecalis* AR01/DGV5 from -219 to +170 relative to the bcrA start codon | This study   |
| **E. coli**                   |                                    |              |
| DH5α                          | supE44ΔlacU169Δ(lacZAM15) hisD17 recA1 endA1 gyrA96 thi-1 relA1 | [39]         |
| XL1-Blue                      | recA1 endA1 gyrA96 thi-1 hisD17 supE44 relA1 lacF’:-3r10 proAB lacZΔlacZAM15 | Stratagene   |
| **E. faecalis**               |                                    |              |
| AR01/DGV5                     | Plasmid-cured clinical isolate; bac’ | [7]          |
| V583                          | Sequenced clinical strain containing plasmids pTEF1, pTEF2, pTEF3; van’ | [40]         |
| **B. subtilis**               |                                    |              |
| W168                          | Wild-type, typC2 | Laboratory stock |
| SGB34                         | W168 thrC::pES702 | This study |
| SGB35                         | TMOB35 thrC::pES702 | This study |
| SGB36                         | TMOB35 thrC::pES702 amyE::pES601; kan’, spc’, cm’ | This study |
| SGB40                         | W168 thrC::pES701 amyE::pES601; spc’, cm’ | This study |
| SGB42                         | W168 thrC::pES702 amyE::pES601; spc’, cm’ | This study |
| SGB43                         | TMOB35 thrC::pES701 amyE::pES601; kan’, spc’, cm’ | This study |
| SGB273                        | TMB1518 sacA::pNTLux101; cm’ | This study |
| SGB274                        | TMB1518 thrC::pES701 sacA::pNTLux101; spc’, cm’ | This study |
| TMOB305                       | W168 bceAB::kan’ | This study |
| TMB1518                       | W168 with unmarked deletions of the bceRS-bceAB, psdRS-psdAB, yxdJK-yxdLM-yxeA loci | This study |
| TMB1560                       | TMB1518 sacA::pCF133; cm’ | This study |
| TMB1562                       | TMB1518 thrC::pCF132 sacA::pCF133; spc’, cm’ | This study |

*Bac, bacitracin; cm, chloramphenicol; fs, fusidic acid; kan, kanamycin; mls, macrolide-lincosamide-streptogramin B group antibiotics; rif, rifampin; spc, spectinomycin; van, vancomycin; r, resistant.

doi:10.1371/journal.pone.0093169.t001

Luciferase assays

Luciferase activities of *B. subtilis* strains were assayed using a Synergy 2 multi-mode microplate reader from BioTek controlled by the software Gen5. LB medium was inoculated 1:500 from overnight cultures, and each strain was grown in 100 μL volumes in a 96-well plate. Cultures were incubated at 37°C with shaking (intensity: medium), and the OD_{600} was monitored every 10 min. At an OD_{600} of 0.02 (4–5 doublings since inoculation; corresponding to OD_{600} = 0.1 in cuvettes of 1 cm light-path length), each bacitracin was added to final concentrations of 0.03, 0.1, 0.3, 1 μg ml^{-1}, or vancomycin to final concentrations of 0.01, 0.025, 0.05, 0.25 μg ml^{-1}; in all cases one well was left untreated. Cultures were further incubated for 2 h, and the OD_{600} and luminescence (endpoint-reads; 1 s integration time; sensitivity: 200) were monitored every 5 min. OD_{600} values were corrected using wells containing 100 μL LB medium as blanks. Raw luminescence output (relative luminescence units, RLU) was normalized to cell density by dividing each data-point by its corresponding corrected OD_{600} value (RLU/OD).
Results and Discussion

Functional transfer of the BcrR-BcrAB bacitracin resistance system to B. subtilis

In E. faecalis, expression of the genes bcrAB that encode the bacitracin resistance transporter BcrAB is controlled solely by the one-component regulator BcrR [14]. This regulator is encoded by a gene directly upstream of the transporter operon, but as an independent transcriptional unit [7]. To test if BcrR could be functionally produced in B. subtilis, we introduced a transcriptional fusion of its target promoter, P_{bcrAB}, to lacZ (pES601), together with an expression construct of bcrR controlled by a xylose-inducible promoter (pES701), into the wild-type strain. Addition of increasing concentrations of bacitracin led to a strong upregulation of promoter activities with a threshold concentration for induction of 0.3 μg ml⁻¹ (Fig. 1A). No promoter activities above background (ca. 1 Miller Unit (MU)) could be detected in a strain lacking BcrR (data not shown), demonstrating that the observed induction was indeed due to BcrR activity. It was shown previously that the sensitivity of BcrR is increased in a strain of E. faecalis lacking BcrAB, and this was attributed to competition between the transporter and BcrR in bacitracin binding [14]. While B. subtilis itself does not contain a BcrAB-like transporter, it nevertheless possesses a transport system for bacitracin resistance, BceAB, belonging to a different family of transporters [28]. To test if this unrelated transporter could also influence the sensitivity of BcrR, we next introduced the expression and reporter constructs into a strain carrying a bceAB::kan deletion (TMB035). Here, the threshold for induction was ten-fold lower at 0.03 μg ml⁻¹ bacitracin, with 0.1 μg ml⁻¹ leading to full induction. Furthermore, the maximal amplitude of induction was significantly increased (p = 0.006) to more than 200-fold (Fig. 1B). Therefore, the BceAB transporter of B. subtilis appeared to decrease the availability of bacitracin for detection by BcrR, similar to the effect of BcrAB in E. faecalis.

We next introduced a construct containing bcrR under control of the xylose-inducible promoter followed by bceAB under BcrR-dependent control of its native promoter (pES702) into TMB035 (bceAB::kan). In this strain, the induction behaviour was comparable to that of wild-type B. subtilis carrying BcrR alone (Fig. 1C). Introduction of the same construct into the wild-type background produced a strain harbouring both transporters, BceAB and BcrAB. While the induction threshold was not significantly altered compared to strains possessing only one transporter, the amplitude of induction was lowered to approximately 50-fold (Fig. 1D). These data clearly show that both BceAB and BcrAB are able to impart bacitracin resistance to the construct of BcrR::kan. In this strain, the induction behaviour was comparable to that of wild-type B. subtilis carrying BcrR alone (Fig. 1C). Further implication that bcrR was expressed in a BcrR-dependent manner in B. subtilis. We therefore wanted to test if this construct was also able to impart bacitracin resistance to the B. subtilis host. The minimal inhibitory concentration (MIC) of bacitracin was strongly reduced from 128 μg ml⁻¹ in the wild-type to 2–4 μg ml⁻¹ in the bceAB-deleted strain TMB035 (Table 3), consistent with earlier reports [20,29]. Introduction of the bcrR-bceAB construct increased the

Table 2. Primers used in this study.

| Primer name | Sequence (5’-3’) | Use |
|-------------|------------------|-----|
| TM1569      | AGGGATCCCTAGGAACGTTTTTCACCAAC | bcrAB rev |
| TM1798      | TAAAGATCTCGAAAGCACCGCTTGATGACG | bcrR f[w]d |
| TM1800      | TAAAGATCTTTTATTCATCCCAATCTCTGC | bcrR rev |
| TM1801      | TAAAGATCTTTTTTGGTGTAACATGGCAAAG | Pm_{Lux} lacZ f[w]d |
| TM1802      | TAAAGATCTTTTATTCATCCCAATCTCTGC | Pm_{Lux} lacZ rev |
| TM2450      | AAATGGATCCGAAACTACAGACTGTTATG | vanR f[w]d |
| TM2451      | AAATGGATCTTTTTATTCATCCCAATCTCTGC | vanS_{xyd} rev |
| TM2452      | AAATGGATCTTTTTATTCATCCCAATCTCTGC | P_{van} f[w]d |
| TM2551      | AAATGGATCTTTTTATTCATCCCAATCTCTGC | P_{van} rev |
| TM2813      | TAAAGATCTTGAAAGCAGTCATTTTC | Pm_{Lux} lacZ rev |
| TM2547      | TAAAGATCTTTTTATTCATCCCAATCTCTGC | P_{van} f[w]d |
| TM2548      | TAAAGATCTTTTTATTCATCCCAATCTCTGC | P_{van} rev |
| TM2549      | TAAAGATCTTTTTATTCATCCCAATCTCTGC | P_{van} f[w]d |
| TM2550      | TAAAGATCTTTTTATTCATCCCAATCTCTGC | P_{van} rev |

*Restriction sites are underlined; overlaps to other primers for PCR fusions are shown by lower case letters.

doi:10.1371/journal.pone.0093169.t002

B. subtilis as Host for E. faecalis Systems

| Primer name | Sequence (5’-3’) | Use |
|-------------|------------------|-----|
| TM1569      | AGGGATCCCTAGGAACGTTTTTCACCAAC | bcrAB rev |
| TM1798      | TAAAGATCTCGAAAGCACCGCTTGATGACG | bcrR f[w]d |
| TM1800      | TAAAGATCTTTTATTCATCCCAATCTCTGC | bcrR rev |
| TM1801      | TAAAGATCTTTTTTGGTGTAACATGGCAAAG | Pm_{Lux} lacZ f[w]d |
| TM1802      | TAAAGATCTTTTATTCATCCCAATCTCTGC | Pm_{Lux} lacZ rev |
| TM2450      | AAATGGATCCGAAACTACAGACTGTTATG | vanR f[w]d |
| TM2451      | AAATGGATCTTTTTATTCATCCCAATCTCTGC | vanS_{xyd} rev |
| TM2452      | AAATGGATCTTTTTATTCATCCCAATCTCTGC | P_{van} f[w]d |
| TM2551      | AAATGGATCTTTTTATTCATCCCAATCTCTGC | P_{van} f[w]d |
| TM2813      | TAAAGATCTTGAAAGCAGTCATTTTC | Pm_{Lux} lacZ rev |
| TM2547      | TAAAGATCTTTTTATTCATCCCAATCTCTGC | P_{van} f[w]d |
| TM2548      | TAAAGATCTTTTTATTCATCCCAATCTCTGC | P_{van} rev |
| TM2549      | TAAAGATCTTTTTATTCATCCCAATCTCTGC | P_{van} rev |
| TM2550      | TAAAGATCTTTTTATTCATCCCAATCTCTGC | P_{van} f[w]d |

*Restriction sites are underlined; overlaps to other primers for PCR fusions are shown by lower case letters.

doi:10.1371/journal.pone.0093169.t002

PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e93169
resistance of the bceAB-deleted strain to 32 µg ml⁻¹ (Table 3). This degree of protection conferred to B. subtilis (i.e. 8- to 16-fold increase in MIC) is the same as that conferred to E. faecalis itself, where BcrAB raises the MIC from 32 µg ml⁻¹ to >256 µg ml⁻¹ [7]. The difference in final resistance reached is due to the differing degrees of intrinsic bacitracin resistance between the two hosts. Additional expression of the E. faecalis transporter in wild-type B. subtilis could not further increase its resistance (Table 3). In fact we have to date been unable to raise the MIC of the wild-type strain, even with overproduction of its native BceAB transporter (own unpublished observation), suggesting that the level of resistance is not limited by transport capacity.

Taken together, our results demonstrate full functionality of the E. faecalis Bcr-system in B. subtilis, both regarding gene regulation and bacitracin resistance. Importantly, however, the native resistance determinants of the B. subtilis host were shown to interfere with the sensitivity and amplitude of promoter induction and masked the resistance imparted by the introduced system. This observation is addressed in the following section.

Development of a sensitive recipient strain

When employing a heterologous host for functional studies of resistance and associated regulatory systems, it is of vital importance to consider any potential interference from intrinsic resistance determinants. One advantage of using B. subtilis as the heterologous host is that its resistance determinants against cell wall antibiotics are very well known. Several proteins were shown to contribute to broad-spectrum protection from charged antimicrobial peptides, for example by modification of teichoic acids in the cell envelope [30], but most of these mechanisms are not drug-specific. In contrast, antimicrobial peptide transporters such as the BceAB system described above, are thought to function by removal of the antibiotic from its site of action [12,20,31–33], and are thus likely to interfere with heterologously introduced

Table 3. Antibiotic susceptibility of B. subtilis strains.

| Strain | Relevant resistance proteins | Bacitracin MIC⁺ (µg ml⁻¹) | Vancomycin MIC⁺ (µg ml⁻¹) |
|--------|-----------------------------|---------------------------|---------------------------|
| W168   | BceAB⁺                      | 128                       | 0.25                      |
| TMB035 | BceAB⁺                      | 2–4                       | 0.25                      |
| TMB1518| BceAB⁺                      | 4                         | 0.25                      |
| SGB34  | BceAB⁺, BcrR-BcrAB⁺         | 128                       | 0.25                      |
| SGB35  | BceAB⁺, BcrR-BcrAB⁺         | 32                        | 0.25                      |

*Minimal inhibitory concentrations (MIC) determined from three biological replicates; where a range of concentrations is given, results varied between replicates.

doi:10.1371/journal.pone.0093169.t003
resistance determinants. *B. subtilis* possesses three paralogous systems of differing substrate specificities: BceAB mediates resistance against bacitracin, mesacandin, actagardine and plectasin [20,31]; PsaAB confers resistance against a broad-range of lipid II-binding antibiotics such as nisin or gallidermin [31]; for XydLM, no role in resistance has been identified to date, but it’s expression is induced in response to the human cathelicidin LL-37 [34]. All three transporters are encoded together with an operon for a two-component regulatory system, BcrRS, PsdRS and XydJK, respectively, which controls expression of its corresponding transporter operon [20,31,35].

To obtain a recipient strain that is well suited for the study of resistance mechanisms against cell wall antibiotics from *E. faecalis* and potentially also other genetically intractable Gram-positive bacteria, we therefore created unmarked deletions of all three entire genetic loci, bcrRS-bceAB, psdRS-psdAB and yycJK-yydLM-yylA-yycL, which is a gene of unknown function that may form a transcriptional unit with yydLM and was therefore included in the deletion. To test for the absence of interference, we then introduced the bcrR expression construct pES701 used above into the triple deletion strain, TMB1518. While our study was in progress, the Lystick-laboratory developed a new reporter system for *B. subtilis*, based on the bacterial luciferase operon luxABCD, which allows time-resolved, semi-automated analyses of transcriptional promoter fusions [23,36]. To test the applicability of this reporter for our purposes, we inserted the BcrR target promoter P_{bcrA} upstream of the lux operon and introduced this construct into the triple deletion strain harbouring BcrR. At high expression levels of BcrR due to induction by xylose, addition of bacitracin to growing cultures of this strain resulted in a rapid response, with a more than ten-fold increase of promoter activity within 5 min after addition of 1 μg ml⁻¹ bacitracin (Fig. 2A). Only background luminescence (ca. 10⁻³ relative luminescence units (RLU) per OD) was observed in the absence of bacitracin or in a strain lacking BcrR (Fig. 2A and data not shown). Analysis of promoter activities 30 min post-induction showed a similar dose-response behaviour (Fig. 2B) compared to the corresponding lac promoter report strain shown above (Fig. 1B). While the threshold concentration for induction appeared slightly increased for the P_{bcrA}-lux construct, possibly due to the different growth conditions in 96-well plates compared to test-tubes, the maximal amplitude of induction was approximately doubled to over 500-fold, which can most likely be attributed to the very low background luminescence obtained with luciferase assays. Therefore both the lac promoter and lux reporters are equally suitable to determine dose-response behaviours of regulatory systems, while the lux reporter offers higher sensitivity and additionally allows time-resolved analyses for dynamic studies.

To test if the cellular protein levels of a one-component regulator like BcrR affected the promoter induction behaviour, the same experiments were also carried out in the absence of xylose, relying on the basal activities of the P_{bcrA}-promoter for bcrR expression (Fig. 2C and D). Under these conditions, the maximal promoter activities were reduced approximately eight-fold (p = 0.0003). Considering that the difference in P_{bcrA} activity in the presence and absence of xylose is ten-fold under the conditions used here [36], this difference in BcrR activity is likely directly due to a reduced copy number of BcrR in the cell. However, the dose-response behaviour was again similar to previous results, with a threshold concentration for induction in the range of 0.03 to 0.1 μg ml⁻¹ bacitracin. Thus the overall function of BcrR was robust to changes in expression, with differences in protein levels merely affecting the amplitude of induction but not the response to the stimulus.

### Qualitative activity assays on solid media for screening applications

To elucidate the molecular mechanisms of stimulus perception and signal transduction in regulatory systems, random or site-directed mutagenesis is often used. Particularly in the case of random mutagenesis approaches, but also for (synthetic) DNA-libraries, assays performed on solid media greatly facilitate screening of large numbers of clones. To evaluate the lac promoter and lux reporters for such applications, the derived BcrR/P_{bcrA} reporter strains were streaked onto agar plates in the absence or presence of bacitracin. Strains harbouring the P_{bcrA}-lacZ fusions showed a blue colouration on XGal-containing agar plates in the presence of inducing concentrations of bacitracin, but remained white in its absence (Fig. 3A and B). As observed before in the quantitative assays, presence of the promoters BceAB or BcrR diminished the intensity of colouration (Fig. 3B, sectors 1 and 2). In the strain possessing both transporters, bacitracin concentrations of at least 10 μg ml⁻¹ were required to produce blue colonies (data not shown), consistent with the low promoter activities reported above for this strain. The reporter strain harbouring BcrR and the P_{bcrA}-lux construct showed strong luminescence when grown on agar plates containing 0.3 μg ml⁻¹ bacitracin, and no detectable luminescence in its absence (Fig. 3C and D).

Both reporter constructs are therefore suitable for screening libraries of clones for promoter induction and are applicable for high-throughput approaches. In principle, screens for loss-of-function as well as gain-of-function mutations can be performed, depending on experimental design. This set-up offers a great advantage over studies performed directly in *E. faecalis*, where it is much more difficult to obtain large numbers of transformants than in the naturally competent *B. subtilis*. Importantly, the output of both promoters is sufficiently sensitive to allow assays to be performed at sub-lethal concentrations of the antibiotic, at least in the case of the Bcr-system. The feasibility of this approach was recently demonstrated in a study that identified essential residues in the *B. subtilis* bacitracin resistance transporter BceAB [29], and the same strategy should be applicable to the heterologous set-up described here.

### Functional transfer of the VanSB-VanR₈ two-component system to *B. subtilis*

Following successful transfer of the Bcr-system of *E. faecalis* to *B. subtilis*, we next wanted to test if our set-up could be applied to other regulatory systems. The two-component system VanS-VanR regulating VanA-type vancomycin resistance had previously been shown to be functional in *B. subtilis* [1]. However, heterologous expression of vanR₈-gramp₈ encoding the regulatory system for VanB-type resistance had resulted in constitutive expression of the target promoter, P_{vanAB} and the authors could show that this was due to constitutive activity of the sensor kinase VanSB under the conditions chosen [18]. To test if vancomycin-dependent modulation of VanS₈ activity could be obtained by optimization of conditions, we introduced an expression construct of the vanS₈-gramp₈ operon under control of the xylose-inducible promoter P_{xyd} into TMB1518. The activity of the two-component system was monitored as activation of a P_{vanAB}-luxABCD operon under control of the xylose-inducible promoter P_{xyd}. Analysis of promoter activities 30 min post-induction showed a similar dose-response behaviour (Fig. 4A). Importantly, and in contrast to previous data, only background activity was observed in the absence of vancomycin
circles) or 1
m
unmarked deletion of
targeted fashion in
mechanisms. Promising results can then be validated in a more
of ligand binding sites and thus to elucidation of sensory
libraries, or chimeric protein fusions, which may lead to discovery
high-throughput screening of random mutants, synthetic DNA
The high degree of competence of
investigations into the respective modes of vancomycin detection.
B. subtilis
be functionally produced in
(Fig. 4A, open circles). The threshold concentration for induction
was 0.01 μg ml⁻¹, and a maximum induction of ca. 500-fold was
observed in the presence of 0.05–0.25 μg ml⁻¹ vancomycin. The
MIC of B. subtilis for vancomycin was determined as 0.25 μg ml⁻¹
for both the wild-type and TMB1518 (Table 3), and therefore
higher concentrations were not tested. In the previous study,
promoter activities were analysed only in the presence of xylose to
ensure high expression levels of the two-component system [18],
which may have led to the high basal activities observed. We
therefore next repeated the induction experiments, but in the
presence of 0.2% xylose, and indeed found ten-fold increased
promoter activities in the absence of vancomycin (Fig. 4B).
Vancomycin-dependent induction was still observed, but only to a
maximum of ten-fold over the uninduced control, due to the
higher basal activity.
To minimize interference from intrinsic resistance determinants
against antimicrobial peptides, we have constructed a B. subtilis
strain devoid of the most efficient systems. This strain should
provide a clean genetic background for the study of a broad range
of resistance mechanisms against cell wall active substances,
particularly regarding their regulation. In addition to one-
component regulation of bacitracin resistance and two-component
regulation of vancomycin resistance implemented here, we have
successfully applied this set-up to the functional reconstitution of a
more complex regulatory and resistance network [37]. It should be

Figure 2. Time-resolved induction of P_{bceA} by bacitracin in an unmarked, sensitive B. subtilis recipient strain. SGB274, carrying unmarked deletion of bceRS-bceAB, psdRS-psdAB, yxdJK-yxdLM-yxeA and harbouring the P_{bceA-lux} reporter construct pNTlux101 and bceR expression construct was grown in the presence of 0.2% (w/v) xylose (panels A and B), or in the absence of xylose (panels C and D). In early exponential phase (t = 0 min), bacitracin was added to final concentrations of 0 (open circles) 0.03 μg ml⁻¹ (open squares), 0.1 μg ml⁻¹ (grey circles), 0.3 μg ml⁻¹ (solid circles) or 1 μg ml⁻¹ (solid squares), and luminescence normalized to optical density (RLU/OD) was monitored. (A, C) Time-course of promoter induction over 60 min after bacitracin-challenge. (B, D) Dose-response at 30 min post-induction; the time point is labelled with the arrow in the panels above. Results are shown as the mean and standard deviation of three biological replicates.

doi:10.1371/journal.pone.0093169.g002

Conclusions
In summary we here show that B. subtilis is well suited to the use
as a host for functional production of regulatory systems that
control resistance against cell wall active compounds in E. faecalis.
Our data also show that care has to be taken regarding the genetic
background of the host strain and that appropriate expression
levels of the regulator genes have to be experimentally determined.
Due to the availability of a range of inducible and constitutive
promoters, for which strength and dynamic behaviour are very
well characterized [36], B. subtilis offers a vast potential for
optimization of expression levels, again supporting its suitability as
a versatile heterologous host. Full functionality of any newly
introduced system should of course be validated by comparison of
its behaviour between B. subtilis and the native host before detailed
mechanistic investigations are commenced.
noted that the response of \textit{B. subtilis} to antibiotics in general is among the best understood of all bacteria investigated to date \cite{38}. This plethora of available data therefore constitutes an ideal basis for construction of new sensitive recipient strains adapted to the study of resistance and regulatory systems also for other classes of antimicrobials.

Further, we showed that the two reporters, \textit{lacZ} and \textit{luxABCDE}, can both be used for qualitative (high-throughput) screening approaches, for example of model libraries, as well as for the quantitative characterization of regulators. Complementation studies with random or directed mutations can thus be initiated in the genetically accessible, highly competent host \textit{B. subtilis}; construction of the desired heterologous strains will be further aided by a recently established and fully validated tool-box of vectors, promoters, reporters and epitope-tags for engineering of \textit{B. subtilis} \cite{36}. We therefore envisage that the system developed here will aid investigations into the molecular mechanisms of sensory perception of antimicrobials and subsequent signal transduction, the first essential step of antibiotic resistance. Furthermore, this set-up should also be applicable to the study of unrelated resistance systems or even regulatory cascades of diverse functions from other genetically intractable Gram-positive bacteria.

\section*{Acknowledgments}

The authors would like to thank Richard Losick for supplying vector pAH328.

\section*{Author Contributions}

Conceived and designed the experiments: SG TM GC. Performed the experiments: CF ES. Analyzed the data: CF ES SG. Wrote the paper: SG CF.

\section*{References}

1. Ulijasz AT, Grenader A, Weisblum B (1996) A vancomycin-inducible \textit{lacZ} reporter system in \textit{Bacillus subtilis}: induction by antibiotics that inhibit cell wall synthesis and by lysozyme. J Bacteriol 178: 6305–6309.
2. Arias CA, Murray BE (2012) The rise of the \textit{Enterococcus}: beyond vancomycin resistance. Nat Rev Microbiol 10: 266–278. doi:10.1038/nrmicro2761.
3. Barna JC, Williams DH (1984) The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol 38: 339–357. doi:10.1146/annurev.mi.38.100184.002011.
4. Bruknik E, de Kruijff B (2006) Lipid II as a target for antibiotics. Nat Rev Drug Discov 5: 321–323. doi:10.1038/nrd2004.
5. Bevins RL, Martin-Porter E, Ganz T (1999) Defensins and innate host defence of the gastrointestinal tract. Gut 45: 911–915.
6. Cotter PD, Hill C, Ross RP (2005) Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 3: 777–788.
7. Manson JM, Keis S, Smith JMB, Cook GM (2004) Acquired bacitracin resistance in \textit{Enterococcus faecalis} is mediated by an ABC transporter and a novel
regulatory protein, BecR. Antimicrob Agents Chemother 48: 3743–3746. doi:10.1128/AAC.48.10.3743–3747.2004.

8. Matos R, Pinto VV, Ruivo M, Lopes M do FS (2009) Study on the dissemination of the BacA/B cluster in Enterococcus spp. reveals that the BacAB transporter is sufficient to confer high-level bacitracin resistance. International Journal of Antimicrobial Agents 34: 142–147. doi:10.1016/j.ijantimicag.2009.02.008.

9. Storm DR, Strominger JL (1973) Complex formation between bacitracin peptides and isoprenyl pyrophosphates. The specificity of lipid-peptide interactions. J Biol Chem 248: 3940–3945.

10. Arthur M, Reynolds P, Courvalin P (1996) Glycopeptide resistance in enterococci. Trends Microbiol 4: 401–407. doi:10.1016/0966-842X(96)10063-9.

11. Arthur M, Quinlivan R (2001) Regulation of VanA- and VanB-type glycopeptide resistance in enterococci. Antimicrob Agents Chemother 45: 373–381.

12. Gebhardt S (2012) ABC transporters of antimicrobial peptides in Firmicutes bacteria - phylogeny, function and regulation. Mol Microbiol 86: 1295–1317. doi:10.1111/j.1365-2958.2011.07735.x.

13. Baptista M, Depardieu F, Reynolds P, Courvalin P, Arthur M (1997) Mutations of the BcrAB transporter and the regulatory protein, BcrR. Antimicrob Agents Chemother 48: 3743–3748. doi:10.1128/AAC.48.10.3743–3747.2004.

14. Gauntlett JC, Gebhard S, Keis S, Manson JM, Pos KM, et al. (2008) Molecular analysis of BecR, a membrane-bound bacitracin sensor and DNA-binding protein from Enterococcus faecalis. J Biol Chem 283: 8391–8600. doi:10.1074/jbc.M709503200.

15. Hong H-J, Hutchings MI, Buttner MJ (2008) Vancomycin resistance VanS/VanR two-component systems. In: Usunri R, editor. Bacterial Signal Transduction: Networks and Drug Targets. Landes Bioscience and Springer Science-Business Media. pp. 200–213.

16. Gebhardt S, Gaballa A, Helmann JD, Cook GM (2009) Direct stimulus perception and transcription activation by a membrane-bound DNA binding protein. Mol Microbiol 73: 482–491. doi:10.1111/j.1365-2958.2009.06787.x.

17. Silva JC, Haldimann A, Prahalad MK, Walsh CT, Wanner BL (1998) In vivo characterization of the type A and B vancomycin-resistant enterococci (VRE) VanKS two-component systems in Escherichia coli: a nonpathogenic model for studying the VRE signal transduction pathways. Proc Natl Acad Sci USA 95: 11951–11956.

18. Biocchia P, Bui NK, Aldridge C, Vollner W, Devine KM (2011) Acquisition of VanR-type vancomycin resistance by Bacillus subtilis: the impact on gene expression, cell wall composition and morphology. Mol Microbiol 81: 157–170. doi:10.1111/j.1365-2958.2011.07684.x.

19. Mascher T, Margulis NG, Wang T, Ye RW, Helmann JD (2005) Cell wall stress responses in Bacillus subtilis: the regulatory network of the bacitracin stimulon. Mol Microbiol 59: 1591–1604. doi:10.1111/j.1365-2958.2005.05368.x.

20. Rietkötter E, Hoyer D, Mascher T (2008) Bacitracin sensing in Bacillus subtilis. Mol Microbiol 68: 768–785. doi:10.1111/j.1365-2958.2008.06194.x.

21. Harwood CR, Cutting SM (1990) Molecular biological methods for Bacillus. Chichester, UK: John Wiley & Sons.

22. Sütte J, Martin-Yevstratova I, Zagorec M, Rose M, Klier A, et al. (1997) Induction of the Bacillus subtilis pgiGH operon by glucose is controlled by a novel antiterminator, GtT. Mol Microbiol 23: 63–70.

23. Schmalies M, Mäue E, Nikolov N, Camp AH, Chevreux B, et al. (2010) Small genes under sporulation control in the Bacillus subtilis genome. J Bacteriol 192: 5402–5412. doi:10.1128/JB.00534-10.

24. Dereg I, Rapoport G, Masek T (2000) The CqsR regulator of stress response is active as a dimer and specifically degraded in vivo at 37 degrees C. Mol Microbiol 38: 335–347.

25. Arnaud M, Chastanet A, Débarbouille M (2004) New vector for efficient allelic replacement in naturally nontransformable, low-GC-content, Gram-positive bacteria. Appl Environ Microbiol 70: 6837–6891. doi:10.1128/AEM.70.11.6837-6891.2004.

26. Clinical and Laboratory Standards Institute (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: 1-64.

27. Miller JH (1972) Experiments in molecular genetics. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.

28. Oki R, Giyanto, Tateo K, Masuayama W, Moriya S, et al. (2003) The BecRS two-component regulatory system induces expression of the bacitracin transporter, BecAB, in Bacillus subtilis. Mol Microbiol 49: 1135–1144. doi:10.1046/j.1365-2958.2003.06355.x.

29. Kalenberg F, Dünner S, Schmutz R, Gebhardt S (2013) Identification of regions important for resistance and signalling within the amoxicillin peptide transporter BecAB of Bacillus subtilis. J Bacteriol 195: 3267–3279. doi:10.1128/JB.00419-13.

30. Kington AW, Liao X, Helmann JD (2013) Contributions of the σ^W, σ^A, and σ^E regulators to the laitobiotic resistance of Bacillus subtilis. Mol Microbiol. doi:10.1111/mmi.12380.

31. Staron A, Finkenisen DE, Mascher T (2011) Peptide antibiotic sensing and detoxification modules of Bacillus subtilis. Antimicrob Agents Chemother 53: 515–525. doi:10.1128/AAC.00352-10.

32. Hiron A, Falord M, Valle J, Débarbouille M, Mascher T (2011) Bacitracin and nisin resistance in Streptococcus aureus: a novel pathway involving the BcrA/BcrB two-component system (SA2417/SA2418) and both the BraD/BraE and VraD/VraE ABC transporters. Mol Microbiol 81: 602–622. doi:10.1111/j.1365-2958.2011.07735.x.

33. Gebhardt S, Mascher T (2011) Antimicrobial peptide sensing and detoxification modules: unravelling the regulatory circuitry of Staphylococcus aureus. Mol Microbiol 81: 381–397. doi:10.1111/j.1365-2958.2011.07747.x.

34. Pietuénan M (2005) Cationic antimicrobial peptides elicit a complex stress response in Bacillus subtilis that involves ECF-type sigma factors and two-component signal transduction systems. Microbiology 151: 1577–1592. doi:10.1099/mic.0.27761-0.

35. Joseph P (2004) Characterization of the Bacillus subtilis YxdJ response regulator as the inducer of expression for the cognate ABC transporter YxdLM. Microbiology 150: 2609–2617. doi:10.1099/mic.0.27155-0.

36. Radcek J, Kraft R, Bartel J, Cakovic T, Durr F, et al. (2013) The Bacillus BioBrick box: generation and evaluation of essential genetic building blocks for standardized work with Bacillus subtilis. Journal of Biological Engineering: in press.

37. Gebhardt S, Fang C, Shaaya A, Leslie DJ, Weimar MR, et al. (2013) Identification and characterization of a bacitracin resistance network in Enterococcus faecalis. Antimicrob Agents Chemother. doi:10.1128/AAC.02111-13.

38. Wecke T, Mascher T (2011) Antibiotic research in the age of omics: from expression profiles to interspecies communication. Journal of Antimicrobial Chemotherapy 66: 2689–2704. doi:10.1093/jac/dkr737.

39. Grant SG, Jesse J, Bloom FR, Hanahan D (1990) Differential plasmid rescue from transgenic mouse DNAs into Escherichia coli methylation-restriction mutants. Proc Natl Acad Sci USA 87: 4645–4649.

40. Sahl DF, Kissinger J, Gilmore MS, Murray PR, Mulder R, et al. (1989) In situ susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 33: 1589–1591.